Hadassah

FDA Grants Approval for US Clinical Trials of Hadassah-Developed Technology to Treat Fatty Liver Disease

Wednesday, Dec 17 2014

A new drug technology, developed at the Hadassah Medical Organization to treat fatty liver disease--a condition with no approved effective drug treatment--was given the go-ahead by the United States Food and Drug Administration (FDA) for a Phase 2 multi-center clinical trial in the US.

In its severe form (called nonalcoholic steatohepatitis-NASH), fatty liver disease can lead to cirrhosis and liver cancer. Current estimates reveal that at least five percent of the Western world’s population suffers from the disease. The majority of these patients also have diabetes, high blood lipids, and obesity.

The new technology was developed by Prof. Yaron Ilan, Director, Department of Internal Medicine and former president of the Israel Liver Association, and his team in Hadassah’s Liver Unit. Based on feeding natural antibodies against intestinal bacteria associated with fatty liver disease, the treatment reduces inflammation by directly affecting the activity level of regulatory T cells in the liver and fat tissues. “The new drug is based on a novel discovery that bacteria in our gut are relevant for the induction of inflammation in our body, which is associated with liver disease, diabetes, and obesity” said Prof. Ilan. “The new therapy is safe and has no side effect, and we hope the results of the phase II trial will enable us to move forward with its development as a treatment for diabetes and fatty liver disease”.

Hadasit, Hadassah’s technology transfer arm, and Immuron, an Australian biopharmaceutical company, worked together to develop the product. The collaborative effort combines Hadassah’s oral immune modulation approach with antibodies produced by Immuron.

The multi-center clinical trial will involve 120 patients in several leading medical centers in the US and Australia. The cohort will receive the treatment for six months, while monitored for the state of their liver disease, diabetes, and lipid profile.

Clinical trials were already conducted at Hadassah, which confirmed the safety and efficacy of the treatment.

Read about the 2009 discovery of treatment for fatty liver disease

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Aug 14 2018

Hadassah Hospital Helps Educate Mikvah Attendants To Bolster Women’s Health

After a woman emerges from the ritual bath (mikveh) and wraps herself in a towel, says mikveh attendant Daniella Salomon, “I keep an eye out” for anything unusual.

READ MORE ›
alt_text

Tuesday, Aug 7 2018

American Medical Attaché and Consulate Nurse Tour Hadassah Hospital Ein Kerem

Jennifer Kmiecinski, Medical Attaché to the Consulate General of the United States in Israel, visited Hadassah Hospital Ein Kerem earlier this month to assess the level of health care available to American personnel serving in Israel.

READ MORE ›
alt_text

Thursday, Aug 2 2018

Thyroid Cancer Diagnosis Enhanced at Hadassah Using Advanced Gene Sequencing

Hadassah Medical Organization researchers, using next generation sequencing (NGS), have identified a highly accurate RNA panel that distinguishes thyroid cancer from benign nodules.

READ MORE ›
alt_text

Thursday, Aug 2 2018

Two Hadassah Ophthalmology Articles Are Among Top 100 Most Cited in Four Decades

Two articles by Hadassah Medical Organization ophthalmologists are among the 100 most cited ophthalmology articles from 1975-2017. One is ranked 11th.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More